PDCD1 and nonpapillary renal cell carcinoma: Based on the CheckMate025 study [7], Nivolumab was identified as the first PD-1 monoclonal antibody approved for the treatment of advanced ccRCC, which significantly prolonged the overall survival of ccRCC patients.